BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turco L, Garcia-Tsao G. Portal Hypertension: Pathogenesis and Diagnosis. Clin Liver Dis. 2019;23:573-587. [PMID: 31563212 DOI: 10.1016/j.cld.2019.07.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen Y, Li J, Zhou Q, Lyu G, Li S. Detection of liver and spleen stiffness in rats with portal hypertension by two-dimensional shear wave elastography. BMC Med Imaging 2022;22:68. [PMID: 35418033 DOI: 10.1186/s12880-022-00786-6] [Reference Citation Analysis]
2 Zuckerman MJ, Elhanafi S, Mendoza Ladd A. Endoscopic Treatment of Esophageal Varices. Clin Liver Dis 2022;26:21-37. [PMID: 34802661 DOI: 10.1016/j.cld.2021.08.003] [Reference Citation Analysis]
3 Kreisel W, Lazaro A, Trebicka J, Grosse Perdekamp M, Schmitt-Graeff A, Deibert P. Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. Int J Mol Sci 2021;22:10372. [PMID: 34638713 DOI: 10.3390/ijms221910372] [Reference Citation Analysis]
4 Rudnick SR, Conway JD, Russo MW. Current state of endohepatology: Diagnosis and treatment of portal hypertension and its complications with endoscopic ultrasound. World J Hepatol 2021; 13(8): 887-895 [PMID: 34552695 DOI: 10.4254/wjh.v13.i8.887] [Reference Citation Analysis]
5 Aquino-Matus J, Uribe M, Chavez-Tapia N. Liver and spleen elastography as predictor of portal hypertension and esophageal varices. Minerva Gastroenterol (Torino) 2021;67:122-8. [PMID: 33337116 DOI: 10.23736/S2724-5985.20.02779-8] [Reference Citation Analysis]
6 Huang Z, Yao Q, Zhu J, He Y, Chen Y, Wu F, Hua T. Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) created using covered stents of different diameters: A systematic review and meta-analysis. Diagn Interv Imaging 2021;102:279-85. [PMID: 33303394 DOI: 10.1016/j.diii.2020.11.004] [Reference Citation Analysis]
7 Kulkarni AV, Arab JP, Premkumar M, Benítez C, Tirumalige Ravikumar S, Kumar P, Sharma M, Reddy DN, Simonetto DA, Rao PN. Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives. Liver Int 2020;40:2888-905. [DOI: 10.1111/liv.14703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Alvarado-Tapias E, Ardevol A, Garcia-Guix M, Montañés R, Pavel O, Cuyas B, Graupera I, Brujats A, Vilades D, Colomo A, Poca M, Torras X, Guarner C, Concepción M, Aracil C, Torres F, Villanueva C. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis. J Hepatol 2020;73:829-41. [PMID: 32298768 DOI: 10.1016/j.jhep.2020.03.048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
9 Zhou H, Hu H, Tian M, Chu J, Tian C, Yang Y, Lin S. Validation and Refinement of the Baveno VI Criteria for Ruling Out High-Risk Varices. Gastroenterol Res Pract 2020;2020:4217512. [PMID: 33376483 DOI: 10.1155/2020/4217512] [Reference Citation Analysis]
10 Manguso G, Vignone A, Merli M, Miotti C, Caputo A, Vizza CD, Badagliacca R. Hemodynamic Evaluation of the Right Heart-Pulmonary Circulation Unit in Patients Candidate to Transjugular Intrahepatic Portosystemic Shunt. JCM 2022;11:461. [DOI: 10.3390/jcm11020461] [Reference Citation Analysis]
11 Shen ZF, Liang X. Current status of radical laparoscopy for treating hepatocellular carcinoma with portal hypertension. World J Clin Cases 2021; 9(11): 2419-2432 [PMID: 33889608 DOI: 10.12998/wjcc.v9.i11.2419] [Reference Citation Analysis]
12 Guixé-muntet S, Zhu C, Xie W, Gracia-sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & Therapeutics 2020;215:107626. [DOI: 10.1016/j.pharmthera.2020.107626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
13 Kreisel W, Schaffner D, Lazaro A, Trebicka J, Merfort I, Schmitt-Graeff A, Deibert P. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. Int J Mol Sci 2020;21:E6223. [PMID: 32872119 DOI: 10.3390/ijms21176223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Catucci D, Obmann VC, Berzigotti A, Gräni C, Guensch DP, Fischer K, Ebner L, Heverhagen JT, Christe A, Huber AT. Noninvasive assessment of clinically significant portal hypertension using ΔT1 of the liver and spleen and ECV of the spleen on routine Gd-EOB-DTPA liver MRI. Eur J Radiol 2021;144:109958. [PMID: 34571458 DOI: 10.1016/j.ejrad.2021.109958] [Reference Citation Analysis]
15 Zanetto A, Barbiero G, Battistel M, Sciarrone SS, Shalaby S, Pellone M, Battistella S, Gambato M, Germani G, Russo FP, Burra P, Senzolo M. Management of portal hypertension severe complications. Minerva Gastroenterol (Torino) 2021;67:26-37. [PMID: 33140623 DOI: 10.23736/S2724-5985.20.02784-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Mauro E, Gadano A. What's new in portal hypertension? Liver Int 2020;40 Suppl 1:122-7. [PMID: 32077610 DOI: 10.1111/liv.14366] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
17 Wang Z, Wu YF, Yue ZD, Zhao HW, Wang L, Fan ZH, Zhang Y, Liu FQ. Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2021; 27(5): 416-427 [PMID: 33584073 DOI: 10.3748/wjg.v27.i5.416] [Reference Citation Analysis]
18 Nardelli MJ, Veiga ZDST, Faria LC, Pereira GHS, da Silva CF, Barbosa FA, Fernandes FF, Perez RM, Villela-Nogueira CA, Couto CA. Noninvasive predictors of esophageal varices in patients with hepatosplenic schistosomiasis mansoni. Acta Trop 2021;226:106283. [PMID: 34919950 DOI: 10.1016/j.actatropica.2021.106283] [Reference Citation Analysis]